European Commission Approves Astellas' XOSPATA(TM) for Patient...
SAN DIEGO, Oct. 30, 2019 /PRNewswire-AsiaNet/ -- Invivoscribe, Inc. announced today that the European Commission (EC) has approved the Astellas drug XOSPATA(TM) (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 ...
Authors: LATEST ASIANET NEWS RELEASES